Why the study?
The pharmacokinetic and pharmacodynamic effects of antiplatelet therapy may be significantly altered in patients with cardiogenic shock after acute coronary syndromes, affecting treatment efficacy.
Does optimal antiplatelet therapy selection improve ischemic complications and survival in patients with acute coronary syndromes experiencing cardiogenic shock?
Does optimal antiplatelet therapy selection improve ischemic complications and survival in patients with acute coronary syndromes experiencing cardiogenic shock?
In the setting of cardiogenic shock, favoring potent P2Y12 inhibitors over clopidogrel and carefully considering early aspirin discontinuation can help mitigate high bleeding and thrombotic risks.
Supports potent P2Y12 inhibitors in AMI cardiogenic shock; leaves open randomized confirmation of survival benefit.
Antiplatelet therapy is critical in patients with acute coronary syndromes experiencing cardiogenic shock (CS) to prevent stent thrombosis and reduce the risk of major adverse cardiac events. Its role is particularly important after percutaneous revascularization; however, the pharmacokinetic and pharmacodynamic effects of antiplatelet therapy may be significantly altered in patients who experience CS. This narrative review discusses the pathophysiologic changes associated with CS that affect antiplatelet agents and provides a concise overview of the related literature on P2Y12 inhibitor selection and the role of aspirin after percutaneous revascularization in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Phillip Weeks (2026) conducted a review in Acute coronary syndromes complicated by cardiogenic shock. Antiplatelet therapy (P2Y12 inhibitors and aspirin) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: